Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2

Authors

Nancy L. Bartlett, Washington University School of Medicine in St. Louis
et al.

Journal

Haematologica

Publication Date

2018

Volume

103

Issue

9

Inclusive Pages

1502-1510

Document Type

Open Access Publication

DOI

10.3324/haematol.2018.192328

Rights and Permissions

Paul M. Barr, et al.. (2018) Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica 103(9):1502-1510. doi:10.3324/haematol.2018.192328. Obtained from the Haematologica Journal website http://www.haematologica.org

Recommended Citation

Bartlett, Nancy L. and et al., "Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2." Haematologica. 103, 9. 1502-1510. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7254